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Abstract
Background: The diagnosis and treatment of patients with chronic obstructive pulmonary disease
(COPD) in Spain continues to present challenges, and problems are exacerbated when there is a
lack of coordinated follow-up between levels of care. This paper sets out the protocol for assessing
the impact of an integrated management model for the care of patients with COPD. The new
model will be evaluated in terms of 1) improvement in the rational utilization of health-care services
and 2) benefits reflected in improved health status and quality of life for patients.
Methods/Design: A quasi-experimental study of the effectiveness of a COPD management model
called COPD PROCESS. The patients in the study cohorts will be residents of neighborhoods
served by two referral hospitals in Barcelona, Spain. One area comprises the intervention group (n
= 32,248 patients) and the other the control group (n = 32,114 patients). The study will include
pre- and post-intervention assessment 18 months after the program goes into effect. Analyses will
be on two datasets: clinical and administrative data available for all patients, and clinical assessment
information for a cohort of 440 patients sampled randomly from the intervention and control
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of-life measures in the two cohorts.
Discussion: The COPD PROCESS model foresees the integrated multidisciplinary management
of interventions at different levels of the health-care system through coordinated routine clinical
practice. It will put into practice diagnostic and treatment procedures that are based on current
evidence, multidisciplinary consensus, and efficient use of available resources. Care pathways in this
model are defined in terms of patient characteristics, level of disease severity and the presence or
absence of exacerbation. The protocol covers the full range of care from primary prevention to
treatment of complex cases.
Background
Chronic obstructive pulmonary disease (COPD), one of
the most common diseases in developed countries, has
become even more prevalent in recent years. In the Span-
ish population aged between 40 and 69 years the preva-
lence is 9.1% (95% confidence interval 8.1%–10.2%)
overall, with rates of 14.3% among men and 3.9% among
women [1]. The prevalence is higher in men and in older
age groups, exceeding 20% in males over the age of 64
years [1]. Rates vary by geographic area, ranging between
4.9% and 18% [2]. COPD has a profound impact on
health and quality of life, particularly in periods of exacer-
bation or acute illness [3]. Given the high prevalence of
COPD in the economically active population in addition
to reports that an estimated 37% of patients experience
limitations in activities of daily living, this disease gener-
ates considerable absenteeism and disability [4].
COPD and exacerbations overload the health-care system,
accounting for 10% of visits to respiratory medicine spe-
cialists and 10% to 12% of primary care consultations [5].
This disease is the third most common reason for hospital
admission (2.5%) and leads to an average stay of 8.4 days
[6]. Over the course of a year, 12.8% of patients with
COPD require hospitalization, 13.8% require emergency
care, and 23.8% visit the doctor monthly [7], generating
an average of €198.17 in direct medical costs per new
diagnosis of COPD per year [5]. The average rises to over
€900 per year for previously diagnosed cases [5]. COPD is
the fourth leading cause of death in developed countries,
preceded only by cancer and cardio- and cerebrovascular
diseases [8]. Projections indicate that it will be the third
leading cause of death worldwide in 2020 and also one of
the main causes of disability and years of life lost [9].
The magnitude and seriousness of the problem contrast
with the fact that COPD is a preventable, treatable and
modifiable disease. COPD begins to develop earlier than
is usually assumed and recognition generally comes when
the disease is already in advanced stages. The rate of
underdiagnosis is alarming. One population-based study
found that 78.2% of cases identified had not been previ-
ously diagnosed [2]. The reasons for this are not well
understood, but many agree that inadequate coordination
between primary and specialized care may play an impor-
tant role [10]. Health-care systems have long been charac-
terized by a lack of cohesion between these two levels, and
even today, no optimal model has emerged to bridge the
gap. Spanish outpatient care has been reformed in recent
years, leading to substantial primary health-care improve-
ments in the public sector. However, the nature of rela-
tions between primary care physicians and specialists has
not been a central concern, contributing to the gap
between the two levels of care and to mutual lack of
understanding. This is of particular importance with
regard to COPD given its high prevalence and wide range
of severity in the patient population. The first attempts at
writing agreements on care for COPD patients were
undertaken by scientific societies only a few years ago
[11], but clear protocols to guide relations between levels
of care, validated to demonstrate their effectiveness and
efficiency, are still lacking. Nor are there studies on which
to base the recommendation of one protocol over
another.
A model for managing the care of COPD patients is still
needed. The aim of such a model would be to integrate
available health-care resources, helping the various clini-
cians involved to agree on a common approach and act in
concert. An ideal, shared model would facilitate coopera-
tion among health-care staff on the basis of well-defined
responsibilities, agreement on working protocols and
mutual exchange of information. It would serve to pro-
mote effective health-care for all patients as well as the
efficient use of resources.
There is relatively little experience with COPD manage-
ment models in different countries and few have been
fully evaluated. The considerable heterogeneity of inter-
ventions applied makes comparison difficult, and most
models also suffer from limited scope, addressing certain
aspects of the disease rather than encompassing preven-
tion as well as care in both stable and exacerbated phases.
Reported models also fail to bring together practices in the
different health-care settings in which professionals work
inside and outside hospitals.Page 2 of 11
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tion. In this respect, although the National Emphysema
Therapy Trial in California, for example, was unable to
demonstrate improvements either in mortality or exercise
tolerance [12], others have managed to achieve benefits
with home- or hospital-based programs. One study found
that exercise tolerance increased, dyspnea decreased and
hospital use declined [13]; another reported that patients
achieved better quality of life on general and respiratory-
disease measures [14].
Models that include patient education for self-manage-
ment of COPD, applying various types of supervision and
support, are also noteworthy in the literature. They have
been shown to produce a long-term effect on hospital
admissions, visits to emergency rooms and sporadic visits
to the doctor [15,16] as well as on quality of life [17]. The
most recent systematic reviews on this topic seem to con-
firm a reduction in hospital admissions but because of the
great heterogeneity of interventions and outcome meas-
ures assessed, it is still not possible to make recommenda-
tions on the manner and content of self-management
training [18,19].
Other care models are based on the multidisciplinary
development, implementation and assessment of clinical
practice guidelines that include tools to support clinical
decision making. Such practice guidelines have been asso-
ciated with a shift away from emergency admissions
toward more planned, scheduled care [20]. The evalua-
tion of health outcomes has shown that quality-of-life
scores on respiratory-disease-specific questionnaires
improve [21] and that there is a moderate positive effect
on lung function [22].
Finally, a few studies have evaluated programs for inte-
grated care, the so-called disease management programs.
These are implemented in specific geographic locations,
are population-based, coordinate different levels of health
care, and offer integrated care, meaning that they encom-
pass interventions related to all stages in the natural his-
tory of the disease. In COPD, these programs have had a
positive impact on certain aspects of patient quality of life
as well as on reducing the number of hospital admissions
and the length of hospital stays [23-27].
In spite of experiences described in the international liter-
ature, however, we still know little of those models and
their impact on COPD patients' health. Nonetheless, the
available evidence does indicate that it is feasible to
develop more cost-effective systems for providing health
care, and that these frameworks have the potential to pro-
vide greater health benefits.
In Spain, several programs, all fragmentary in their scope,
have used markedly diverse approaches and interven-
tions. For example, one group who evaluated the short-
and long-term effects of a pulmonary rehabilitation pro-
gram in a randomized clinical trial, found significant ben-
efits on perceived breathlessness, on 6-minute walk test
results, on several domains of the Chronic Respiratory
Questionnaire (CRQ), and on the number of exacerba-
tions [28]. Hospital admissions, however, were not
reduced. Another trial on pulmonary rehabilitation is
being carried out in 16 primary health-care centers in the
autonomous community of Madrid; its results are not yet
published [29]. Yet another group of researchers, in the
PADOC Project, tested a program to increase the rate of
diagnosis of COPD [30]. Targeting undiagnosed individu-
als with risk factors, the program was implemented in the
primary care setting under the supervision of a large teach-
ing hospital. Spirometry was performed by 194 primary
care physicians and later confirmed by respiratory medi-
cine specialists at the referral hospital. The diagnosis of
COPD was confirmed in 55% of the cases in that trial. Var-
ious Spanish programs have sought to reduce admissions
and shorten hospital stays for exacerbations. A program in
the Basque Country sent a nurse specialist to the homes of
patients who were discharged in less than 4 days [31]. The
CHRONIC program in Barcelona tested a protocol for the
coordination of primary care resources available to
patients after discharge [32-34]. That program provided a
nurse case manager and relied on telephone support for
patients. Both programs led to significant reduction in the
use of hospital services in the test groups compared to the
control groups, with regard to admissions, readmissions,
and duration of hospital stay. Patient satisfaction was also
greater in the intervention group. The PRICE program for
the integrated care of patients with COPD, currently being
implemented by respiratory medicine and primary care
physicians in the autonomous community of Madrid, is
also noteworthy for its combination of all the characteris-
tics required of a clinical management system [35]. PRICE
defines a multidisciplinary framework for health care,
coordinating all care levels, and provides unified guide-
lines for all professionals involved. The aim is to improve
patient care and achieve more rational use of available
resources. Finally, the AUDIPOC project is now under
way [36]. This multicenter study in 7 Spanish autono-
mous communities aims to improve the quality and effec-
tiveness of clinical care given to patients with exacerbated
COPD; the method is based on nationwide clinical audits
and the establishment of guidelines for clinical manage-
ment of exacerbations.
At this time, the COPD PROCESS protocol is being imple-
mented by Hospital de la Santa Creu i Sant Pau in Barce-
lona in conjunction with the primary care teams this
hospital serves. PROCESS is based on the assumption that
the patient is the center and origin of all health-care activ-
ities intended to prevent or address his or her clinical
manifestations. In so doing, PROCESS applies an ambi-Page 3 of 11
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cians and nurses in all the medical specialties that are
relevant to the treatment of COPD. A series of multidisci-
plinary interventions have been established with a view to
integrating the various aspects of the disease and coordi-
nating levels of care. The model attempts to offer a practi-
cal, useful tool for patient care and to avoid becoming yet
another expert consensus statement with scarce following
and negligible impact.
This paper sets out the means through which the effective-
ness of this clinical management model will be assessed.
The overall purpose of the evaluation is to provide evi-
dence on the degree of control of the disease achieved and
on the improvements in the management of patient care,
as well as to determine the impact on health outcomes
and quality of life. PROCESS is intended 1) to improve
patient care delivery, particularly through rational use of
primary and specialist care, and 2) to promote health and
quality of life, both in comparison with the conventional
health-care delivery system in the same city. The principal
endpoints of the study will be the rate of hospital admis-
sions and quality of life.
The hypothesis to be tested is that the PROCESS model
provides effective health-care management that uses avail-
able resources more efficiently and that greater clinical
benefit comes as a result. If we confirm this hypothesis, we
will make available a health-care model of demonstrated
effectiveness, from which we will be able to contribute to
improving the quality of care given to patients with
COPD.
Methods/Design
A quasi-experimental design based on comparison of two
non-randomized groups was chosen to assess the effec-
tiveness of the multidisciplinary, multicenter COPD
PROCESS management model. The intervention group
will consist of all patients with COPD in the area served
by Hospital de la Santa Creu i Sant Pau in Barcelona. The
control group will comprise all COPD patients in the area
served by Hospital de la Vall d'Hebron, also in Barcelona.
Randomization was not feasible because only health-care
professionals within the intervention area can undertake
the coordinated care protocols necessary for implement-
ing the PROCESS protocol. The study will include pre-
and post-intervention assessment after 18 months (Figure
1). This project and the study were presented to and
approved by the Clinical Research Ethics Committee of
Hospital de la Santa Creu i Sant Pau.
Setting
The study will be carried out in the patient populations
registered with primary care centers within the areas
assigned to the respective referral hospitals. The study
group will come from 17 primary care centers, of which
10 are managed by the Catalan Health Institute (ICS) and
7 by other types of health-care provider (private for-profit,
private nonprofit, and mixed public-private entities). The
population base was 322,478 inhabitants over the age of
14 years. The prevalence of COPD in this population was
estimated by age and gender from the results of the IBER-
POC study [2] and the Catalan Health Survey of 2002
[37]; based on those studies, we expect 32,114 COPD
patients (prevalence 8.18%). The control group will also
come from a health-care area comprising 17 primary care
centers, all of which pertain to the ICS (307,668 inhabit-
ants over the age of 14 years; 32,248 patients).
Type of participant
All patients over 20 years old whose primary health-care
medical records included any of the international disease
classification codes related to COPD (Table 1) will be con-
sidered COPD patients and candidates for enrollment.
Diagnostic codes for chronic obstructive asthma (with
COPD), bronchiectasis, extrinsic allergic alveolitis, and
respiratory failure will be excluded. Given that there are
records for individuals classified as having COPD but who
cannot be located for a variety of reasons (for example,
change of address or change or primary care clinic), we
will include only those who have attended a medical visit
or picked up prescriptions within the past year. All
patients so-diagnosed with COPD will be included in
both the intervention and control areas.
Additionally, a cohort will be selected in order to analyze
the clinical and health-care variables. These patients must
also meet the following additional inclusion criteria: 1) be
able to perform spirometry; 2) meet spirometry criteria for
a diagnosis of COPD: lung disease characterized by irre-
versible airflow limitation defined by a ratio of forced
expiratory volume in 1 second [FEV1] to forced vital
capacity ≤70% after a negative bronchodilator test, and in
case of a positive postbronchodilator test (an increase in
FEV1 of >12% and >200 mL after the use of 400 μg of salb-
utamol) not having a personal history of asthma, symp-
toms of atopy or a smoking habit of <40 pack-years.
Additional exclusion criteria for this cohort were 1) a diag-
nosis of any terminal disease that indicates a survival
prognosis <6 months, 4) advanced heart failure, 5) seque-
lae of pulmonary tuberculosis, and 6) lung cancer. All
patients will have to give their written, informed consent
to be enrolled.
Patients with other respiratory or nonrespiratory diseases
can be included in the study provided they do not inter-
fere with measurements. The testing of patients in a
period of COPD exacerbation will generally be postponed
until the disease has been stable for at least one month.
Patients with exacerbated disease will not be excludedPage 4 of 11
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exacerbations, the patient will be tested in that clinical
state.
Calculation of the cohort size: For two-tailed compari-
sons, accepting an alpha risk of 0.05 and a beta risk of 0.2,
to detect a statistically significant between-group CRQ
score increment of 0.5 points (the minimum clinically sig-
nificant difference) [38], and assuming a homogeneous
standard deviation of 1.7 and a loss to follow-up of 10%,
we have calculated that 220 patients will be required in
each cohort. A simple random sampling procedure will be
used to select the cohort patients.
The COPD management model
The COPD PROCESS system was conceived through con-
sensus among all the health-care professionals at different
levels of the system; this included agreement on medica-
tions between community and primary-care pharmacists.
A description of the project has been published [39] and
a series of brochures have provided a summary. Clinical
practice protocols for each phase of the disease have been
defined in accordance with the recommendations of the
Global Initiative for Chronic Obstructive Lung Disease
(GOLD) [40] and two Spanish national guidelines: the
most recent version of the recommendations of the Span-
ish Society of Pulmonology and Thoracic Surgery (SEPAR)
[41] and the consensus paper of the Spanish Society of
Family and Community Medicine (semFYC) [42]. The
result is a set of algorithms and care pathways reflecting
essential diagnostic and therapeutic protocols that have
been adapted to conditions in the local health-care sys-
tem. PROCESS proposes a clinical management program
for COPD that places the patient at its center and inte-
grates care within routine clinical practices at different lev-
els. Resources are organized to provide the best possible
care and treatment through coordinated multidisciplinary
actions (Figure 2).
Clinical recommendations under the COPD PROCESS
model are defined in accordance with patient characteris-
tics and level of disease severity, and the presence or
absence of exacerbation. The recommendations, which
are not dependent on the setting where health care is
delivered, are grouped as follows: 1) prevention (general
and specific interventions that target smoking depend-
ency); 2) diagnosis and determination of severity based
on GOLD criteria [39]; 3) education (basic information
for the patient with COPD); 4) monitoring (periodic fol-
low-up for the patient whose disease is stable and not
severe, or stable and severe, or very severe); 5) treatment
of exacerbated non-severe and severe COPD; and 6) home
care for the COPD patient by means of three programs.
The first (the PAD-MPOC-AH program) addresses the
needs of the discharged patient. In this program, the pri-
mary care team receives discharged patients within the
first 72 hours after they arrive home. The second (PAD-
MPOC-IF) is designed to manage situations of frequent
admission by bringing together primary and specialist
health-care professionals in a committee to take charge of
the treatment and follow-up of frequently-admitted
patients. The third program (PAD-MPOC-VM) will
address the needs of patients receiving home noninvasive
ventilation.
Each set of recommendations in the PROCESS manage-
ment model defines interventions and care in the follow-
ing categories: 1) medical history, physical examination,
and diagnostic tests; 2) pharmacologic and non-pharma-
cologic therapies (smoking cessation, pulmonary rehabil-
itation, nutritional, education, oxygen therapy, and
noninvasive ventilation); and 3) follow-up that is coordi-
nated between the levels of care in accordance with a
model of mixed consultation and direct care, including
criteria for referral, admission to a conventional hospital
ward or treatment in intensive or specialized intermediate
care units.
The implementation of the model rests on five types of
action that have been undertaken in the preliminary
phase. The first involves the formation of working groups
and the identification at each primary care center of two
referees, a physician and a nurse, who will be responsible
for the program at that facility. Second, the physicians and
Design and evaluation of the COPD PROCESS model, a multidisciplinary disease management program for chronic obs ructive pulmonary diseaseFigure 1
Design and evaluation of the COPD PROCESS 
model, a multidisciplinary disease management pro-
gram for chronic obstructive pulmonary disease. 
COPD indicates chronic obstructive pulmonary disease.
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primary care center. These sessions will explain the clini-
cal practice protocols and care pathways in the PROCESS
management program. This action will also involve
explaining the project to the health-care facilities' admin-
istrators and managers; official institutional approval and
involvement will thereby be assured. The third will
involve professional development and training through
1) a session in each primary care center, 2) training for a
group of nurses, and 3) the preparation of patient educa-
tional support materials. The fourth set of activities will
investigate the manner of performing spirometry at each
primary care center. Based on the findings, the primary
and tertiary care staffs will develop systems for calibrating
equipment and assuring the quality of spirometries Train-
ing sessions will be set up to show primary care physicians
and nurses how to perform and interpret spirometry. The
fifth preliminary-phase action will be the introduction of
a software application into the medical records of the pri-
mary health-care teams. This application will support
clinical decision-making in accordance with the PROCESS
protocols. This software is currently being developed by
the ICS.
These five preparatory actions were begun in 2006. The
preliminary phase is scheduled to be completed by the
end of 2008, after which the clinical management pro-
gram will be implemented in its entirety. None of the
aforementioned actions will take place in the centers
located in the control area of the city's health-care system.
Table 1: International disease classification codes for chronic obstructive pulmonary disease on which patient inclusion will be based.
ICD-10 ICD-9 ICPC
J41 Simple and mucopurulent chronic 
bronchitis
490 Bronchitis, not specified as acute or 
chronic
R79 Chronic bronchitis
J41.0 Simple chronic bronchitis 491 Chronic bronchitis
J41.1 Mucopurulent chronic bronchitis 491.0 Simple chronic bronchitis
J41.8 Mixed simple and mucopurulent 
chronic bronchitis
491.1 Mucopurulent chronic bronchitis
491.2 Obstructive chronic bronchitis
491.20 Obstructive chronic bronchitis – 
without exacerbation with the 2004 code 
modification: Emphysema with chronic 
bronchitis – without exacerbation
J42 Unspecified chronic bronchitis 491.9 Unspecified chronic bronchitis
J43 Emphysema 492 Emphysema
J43.0 MacLeod's syndrome 492.0 Emphysematous bleb
J43.1 Panlobular emphysema 492.8 Other emphysema
J43.2 Centrilobular emphysema
J43.8 Other emphysema
J43.9 Emphysema, unspecified
J44 Other chronic obstructive pulmonary 
disease
491.21 Obstructive chronic bronchitis 
with acute exacerbation with the 2004 
code modifications:
R95 COPD 
(chronic obstructive pulmonary disease)
J44.0 Chronic obstructive pulmonary 
disease with acute lower respiratory 
infection
Acute bronchitis with chronic obstructive 
pulmonary disease (COPD)
J44.1 Chronic obstructive pulmonary 
disease with acute exacerbation, unspecified
Acute and chronic obstructive bronchitis
J44.8 Other specified chronic obstructive 
pulmonary disease
Emphysema with acute and chronic bronchitis
J44.9 Chronic obstructive pulmonary 
disease, unspecified
Acute exacerbation of chronic obstructive 
pulmonary disease (COPD)
Excluded: chronic obstructive asthma with acute 
exacerbation (493.22)
491.8 Other chronic bronchitis
496 Chronic airway obstruction, not 
elsewhere classified
ICD = International Classification of Diseases, with modifications approved by the World Health Organization
ICPC = International Classification of Primary Care (WONCA – World Organization of Family Doctors)Page 6 of 11
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applied there. The care of COPD patients in the control
area will continue according to the usual practices of phy-
sicians in those centers.
Study variables
Table 2 shows the variables measured for the study [43-
46]. Two complementary dimensions of the PROCESS
model will be measured. One involves health-care man-
agement. To assess that dimension, clinical and adminis-
trative data for the entire population will be extracted
from the records of the participating centers. The inclu-
sion of this dimension addresses the issue of the impact
on the health-care system (objective 1). The second, clin-
ical dimension will be evaluated on the basis of data from
the intervention and control cohorts. For that purpose,
data will come from both medical records and visits with
patients. The assessment of this dimension corresponds to
the evaluation of patient health and quality-of-life bene-
fits (objective 2).
All measurements will be recorded at the start of the study
and after 18 months' experience implementing the man-
agement program.
Data collection and analysis
Figure 1 shows details of analysis of the pre- and post-
intervention data.
The clinical and administrative information systems at the
primary care centers are computerized (eCAP in the ICS
centers and other applications such as the OMI-AP or
SinAPsis in other centers). Primary care physicians in the
intervention area will also be using PROCESS software
linked to these applications. That software will serve two
functions: it will guide decisions to bring them into line
with the PROCESS recommendations and will also pro-
vide a place to record the actions taken. The participating
hospitals also have computerized clinical and administra-
tive information systems for outpatient, emergency, and
day-hospital activity as well as admissions. The data will
be merged into a single COPD patient registry for each of
the areas (intervention and control). Patients will be iden-
tified by their personal identification code. Information in
this registry will, if possible, be complemented with infor-
mation from records of prescriptions for outpatient respi-
ratory therapy, from the Minimum Basic Data Set for
discharged patients, from records of pharmaceutical pre-
scriptions filled, and from the death registry of the Depart-
ment of Health of the Government of Catalonia
Participating centers and the care pathways of the COPD PROCESS modelFigure 2
Participating centers and the care pathways of the COPD PROCESS model. COPD indicates chronic obstructive 
pulmonary disease.
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records of an allied social-welfare and health-services pro-
gram (Centre Palau).
The clinical data of each patient in each cohort will be col-
lected by two nurses experienced with COPD manage-
ment who will go to the primary care center of each
patient. There they will systematically extract information
from the medical records (medical history and other doc-
uments in digital form or on paper). They will interview
each patient to check the inclusion criteria, obtain
informed consent, ask questions relevant to the outcome
measures, perform lung function tests, and administer a
questionnaire about health-related quality of life.
Statistical analysis
Patients with COPD in the intervention and control areas
will first be described using parameters of point estima-
tion and their 95% confidence intervals. The groups will
then be compared based on bivariate hypotheses on pre-
to post-intervention changes in process and outcome var-
iables. The statistical tests that will be used will depend on
the nature of the variable studied.
Analysis of the health-care dimension will focus on the
impact of the COPD PROCESS model within the health-
care delivery system (objective 1), based on comparing
the utilization of resources and visits to primary and spe-
cialist care facilities in the intervention and control areas.
The principal outcome measure will be the change in
annual rate of scheduled and unscheduled admissions
that are made with a main diagnostic code of COPD
(Table 1) or another code related to a respiratory system
process. The year prior to implementation of the PROC-
ESS management system will be compared to the last 12
months of implementation. The difference between the
rates of the two study areas will be estimated using the
indirect standardization method in which the population
assigned to each health-care area will be used as the stand-
ard. If possible, a more precise analysis of the differences
Table 2: Study variables for the evaluation of the COPD PROCESS
Group Variables
Social and demographic characteristics:†‡ Primary care clinic assignment; date of birth; sex.
Patient and lung function characteristics:‡ Weight; height; spirometry performed in the past year.
Spirometry results after bronchodilator (Datospir 120, model A, SIBEL, S.A, Barcelona, Spain; after 
calibration, with daily maintenance by expert nurses, and quality assurance).
Carbon monoxide in expired air; pulse oximetry; COPD stage (GOLD criteria); year COPD was 
diagnosed.
Clinical status (last 6 months):†‡ Smoking (frequency, pack-years, cessation phase, enrollment in a cessation program, adherence to 
recommended preventive measures); exercise (type of activity, duration in minutes and days per 
week); adherence to any medical advice that has been given; Charlson comorbidity index [43]; 
dyspnea severity (Medical Research Council Breathlessness scale [44]).
Medication:‡ Active principle and pharmaceutical class, dosage.
Inhalers: number of inhaler devices used in the last month, level of handling expertise (correct 
performance of 3 actions for a specific inhaler type).
Oral medications (glucocorticosteroids, theophylline, antioxidants) and their agreement between the 
patient's report and the medical record.
Supplemental oxygen therapy; mechanical ventilation; annual vaccination or in the previous winter 
(flu, pneumococcus)
Attendance at COPD management training sessions or specific sessions related to medication type.
Deviations from the PROCESS model (lack of agreement between drugs taken and those 
recommended for the recorded GOLD severity stage).
Exacerbations in the last year:†‡ Defined as the worsening of respiratory symptoms requiring treatment with antibiotics or oral 
corticosteroids or both (moderate exacerbation) or hospitalization (severe exacerbation) or a 
combination of the two degrees of severity (based on [45])
Complications and potential complications:‡ Primary care nursing diagnosis (according to the Catalan Health Institute's adaptation of the North 
American Nursing Diagnosis Association (NANDA), February 2003).
Health care in the past year:†‡ Primary care clinic visits for any reason (including the general practitioner, the nurse or the 
respiratory medicine specialist); number of home visits made in the past year; number of visits to 
hospital (outpatient, emergency, admissions).
Quality of life:‡ Respiratory-disease related quality of life (Chronic Respiratory Questionnaire [46])
Systemic inflammatory status:‡ C-reactive protein (capillary blood levels: QuikRead® CRP 101. Orion Diagnostica, Espoo, Finland)
Other:†‡ Exitus
† Measures evaluating the health-care dimension of the COPD PROCESS model. Information will be gathered on the population of patients with 
chronic obstructive pulmonary disease in each of the two study areas (clinical and administrative data from the databases of the participating 
centers).
‡ Measures to evaluate the clinical dimension of the COPD PROCESS model. Information will be gathered on patients in the intervention and 
control cohorts by consulting patient medical records and arranging for patient visits in each of the centers.Page 8 of 11
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regression models adjusted for the distribution of the
dependent variable (negative binomial, Poisson, beta), a
procedure which corrects for confounding factors.
For the clinical dimension, health status and quality of life
will be compared between patients in the intervention
and control areas (objective 2). The main outcome meas-
ure will be minimal clinically significant differences
between pre- and post-intervention quality-of-life scores.
A test of comparison between two independent means
will be used for comparisons with the control group. If
multivariate analysis is necessary, multiple regression
models will be constructed.
Discussion
The COPD PROCESS evaluation study offers a unique
opportunity to learn about the performance of a health
management model that is integrated, multidisciplinary,
adapted to conditions in Spain and possibly appropriate
for countries with similar characteristics. The knowledge
gained will be an important contribution given that few
full descriptions of such experiences are available in the
literature. If we are able to demonstrate the feasibility and
benefits of the PROCESS model, a substantial innovation
in health-care organization will become available. Objec-
tive, scientific evidence of the impact of a model of health-
care delivery on COPD in terms of patient health and
quality of life will be of great importance and help palliate
the considerable morbidity and mortality this disease
causes. The result will be a better system in which
resources for patient care are handled more rationally and
efficiently to deliver higher quality health care.
Although the fact of implementing the model in a local
health-care area may suggest that the results cannot be
extrapolated to other settings with different characteris-
tics, the intervention area has no singularly differentiating
characteristics and the project will require no investment
of resources other than those usually available to any sim-
ilar health-care system. This project therefore has the
external validity necessary to generalize the results to at
least the Spanish national health-care system and assure
that the impact it might have on health and the health-
care system will be highly relevant.
Strengths and possible limitations of the study
The limitations inherent to any evaluative or quasi-exper-
imental study are also present in this research. Patients
cannot be randomized for this study. Nonetheless, the
design is the most robust one available and will provide
the strongest evidence possible, within the existing con-
straints. Possible differences that might emerge between
the control and intervention groups will be adjusted by
applying multiple regression analysis.
The use of clinical and administrative databases as sources
of information places limitations on the comprehensive-
ness of the analysis and its validity, as the quality of data
is dependent on the information storage interface and its
adequate and proper use by health-care professionals. It
was expressly decided, however, not to create dedicated
databases given that the pragmatic nature of the model
requires that the information sources be integrated into
the daily work routines of the physicians and nurses who
are caring for the patients. The inclusion of the study
cohorts will counterbalance this limitation.
Implementing a multidisciplinary model over such an
extensive geographic area and working with such a large
number of clinical caregivers is a complex undertaking.
Adequate and consistent adherence to the PROCESS pro-
tocols at all the health-care facilities will require a very
high level of dedication. Therefore, it will be essential to
integrate the project-specific software into the records of
the care facilities. Periodic meetings to coordinate and
supervise the participants will also be required.
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